2 private satellites undock after pioneering life-extension mission
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Two commercial satellites have completed an undocking maneuver high above Earth, signaling the successful end to a pioneering spacecraft life-extension mission.
The Mission Extension Vehicle-1 (MEV-1), developed by Northrop Grumman Corporation's Space Logistics LLC, docked with Intelsat's IS-901 communications satellite in 2020 in a graveyard orbit, a few hundred miles above geosynchronous orbit (GEO), an orbital belt 22,236 miles (35,786 kilometers) above Earth.
MEV-1, which launched atop a Russian Proton rocket in October 2019 from Baikonur Cosmodrome in Kazakhstan, then brought IS-901 back to GEO and allowed it to restart its operations. But now, after extending the life of IS-901 for five years, the mission has come to an end.
IS-901 has been taken back into the GEO graveyard — where decommissioned satellites are positioned to remove them safely from the active GEO belt — by MEV-1. There, the two spacecraft undocked. Just as the 2020 rendezvous was the first docking between commercial spacecraft in GEO, this marks the first such commercial undocking.
Related: Watch Northrop Grumman's MEV-1 dock with Intelsat 901!
This is not the end for MEV-1, however, as the spacecraft is currently relocating to the next servicing mission, according to Northrop Grumman. This is all part of the company's plans to provide life-extension services for satellites in GEO.
"The first-of-its kind technology that extended a satellite's life is paving the way for an entire infrastructure of future on-orbit satellite servicing missions for a variety of customers," Rob Hauge, president of Northrop Grumman Space Logistics, said in an April 9 statement. "We are continuing to invest in next-generation capabilities to deliver the most technologically advanced servicing capabilities to support and maintain new and existing space-based assets."
MEV-1 is not the only player in the satellite life-extension game. Northrop Grumman Space Logistics' follow-on spacecraft, MEV-2, is currently docked to Intelsat 10-02 and will continue providing life-extension services for an additional four years.
— Private Astroscale probe will refuel Space Force satellites high above Earth on landmark 2026 mission
— Ailing Intelsat satellite begins new life in orbit after historic servicing mission success
— NASA cancels multibillion-dollar on-orbit satellite servicing mission
The U.S. Space Force also recently tapped Northrop Grumman for the Elixir refueling payload program, which will "enable the Space Force to refine tactics and procedures for rendezvous and proximity operations, docking, refueling, and undocking of on-orbit vehicles," according to a different Northrop Grumman statement.
Meanwhile, Astroscale U.S. will attempt to refuel a pair of Space Force spacecraft in 2026, following an announcement at the 40th Space Symposium in Colorado Springs earlier this month. Elsewhere, China launched its own experimental refueling spacecraft, Shijian 25, in January this year.
Countries and companies are pursuing life extension and satellite-servicing capabilities for a range of uses and reasons, including reducing space debris, potential cost savings and enabling flexible and sustainable satellite operations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Satellite image of an Iranian airport shows an American-made F-14 Tomcat that Israel turned into a burned wreck
The Israeli military said it bombed two Iranian F-14 Tomcats in Tehran earlier this week. A new satellite image shows that one of the fighter jets is destroyed while the other looks damaged. The US sold dozens of F-14s to Iran in the 1970s when the two countries still had ties. New satellite imagery of an Iranian airfield shows two US-made F-14 fighter jets — one of which looks to be totally destroyed — after they were hit by Israeli airstrikes earlier in the week. The image, captured on Friday by US commercial satellite imaging company Maxar Technologies and obtained by Business Insider, shows the two F-14s at a facility at Mehrabad International Airport in Tehran. One of the F-14s appears to have taken a hit near the nose, although the full extent of the damage is unclear. However, the other jet directly next to it was reduced to a burned wreck. Brig. Gen. Effie Defrin, a spokesperson for the Israel Defense Forces, said on Monday that an IDF drone struck two Iranian F-14s, marking "another loss of strategic weaponry for the enemy." The military published footage showing a direct hit on each aircraft. The F-14 Tomcat is a multi-role fighter jet made by the US aerospace corporation formerly known as Grumman Aerospace Corporation, now Northrop Grumman. Designed to be launched from aircraft carriers, the plane was introduced by the US Navy in the 1970s and participated in combat missions around the world over the next few decades. The Navy stopped flying the F-14 in 2006, after replacing it with the F/A-18 Super Hornet made by US defense manufacturer Boeing. However, the F-14 has remained a celebrated aircraft, in part because of its spotlight in the "Top Gun" blockbusters. The US sold nearly 80 F-14s to Iran, once an American partner, before the 1979 Iranian Revolution ended relations between the two countries. Washington cut support and supplies of spare parts for the Tomcats, and Tehran's inventory slowly declined over time as maintenance and logistical challenges mounted. Iran still has its jets, though, and is the only remaining operator. Iran's F-14s, like much of its air force, are relatively obsolete due to international sanctions and embargoes that prevent the country from modernizing its fleet. Tehran also operates other aging aircraft, including Soviet-era Su-24s and MiG-29s and US-made F-5s. The limitations of its airpower have forced Iran to rely on building a large arsenal of ballistic missiles and attack drones. Tehran was said to have purchased newer Su-35 aircraft from Russia, although it's unclear if any have been delivered. Israel has struck additional aircraft beyond the two F-14s, including at least one aerial refueling tanker and eight attack helicopters, since beginning a new operation last Friday aimed at degrading Iran's nuclear program, a longtime goal of Prime Minister Benjamin Netanyahu. Over the past week, Israeli fighter jets have carried out widespread airstrikes across Iran, targeting its nuclear facilities, top scientists, senior commanders, missile launchers, air defenses, and other high-profile military infrastructure. The Iranians have responded by launching hundreds of missiles and drones at Israel. Meanwhile, President Donald Trump is weighing whether to use US assets to strike Iran's most hardened nuclear sites. Iran has said that it will retaliate if American forces intervene in the conflict. Read the original article on Business Insider
Business Upturn
12 hours ago
- Business Upturn
Novo Nordisk's subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
By GlobeNewswire Published on June 21, 2025, 04:34 IST Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American Diabetes Association (ADA) Scientific Sessions. 1,2 and presented at the American Diabetes Association (ADA) Scientific Sessions. Oral amycretin phase 1 data on the safety, tolerability and weight loss potential in people with overweight or obesity was also published in The Lancet. 3 Findings from the clinical trials indicate amycretin appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists.1,2,3 Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85 th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity were published today in The Lancet medical journal.1,3 Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule. The published and presented results from the once-weekly subcutaneous amycretin phase 1b/2a clinical trial showed that participants who received the treatment demonstrated significantly greater weight loss across the full range of doses investigated compared to placebo. Data being presented at ADA were collected from two parts of the trial; dose escalation (amycretin 60 mg), and dose escalation and maintenance (amycretin 20 mg, 5 mg and 1.25 mg).1,2 No plateauing in weight reduction was observed at the end of treatment (ranging from 20 to 36 weeks) with all tested doses, suggesting that a longer treatment duration may potentially contribute to additional weight loss.1,2 Estimated mean change in body weight from baseline with once-weekly subcutaneous (SC) amycretin: 1,2 * Dose Treatment % Weight change % Weight change duration (SC amycretin) (placebo) 60 mg 36 weeks -24.3% -1.1%20 mg** 36 weeks -22.0% 1.9%5 mg** 28 weeks -16.2% 2.3% 1.25 mg** 20 weeks -9.7% 2.0% * If all people adhered to treatment i.e. if all people followed the planned dosing schedule for the full trial period without any treatment discontinuations. ** Administered during a 12-week maintenance period. Once-weekly subcutaneous amycretin treatment escalated up to 60 mg appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists.1,2 The number of treatment-emergent adverse events (TEAEs) increased in a dose-dependent manner, were mostly gastrointestinal, and were comparable to the rate and profile of TEAEs reported in early-phase studies of GLP-1 receptor, GLP-1 receptor/gastric inhibitory polypeptide (GIP) receptor, and amylin receptor agonists.1,2 The majority of TEAEs were mild to moderate in severity and resolved by the end of the study period.1,2 Of the participants who discontinued the trial, the majority were due to non-TEAE reasons.1,2 'As pioneers in obesity innovation, we are exploring multiple biological pathways to develop potentially transformative medicines that support the individual needs and preferences of people with obesity on their weight loss journey towards overall improved health,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk . 'Amycretin is the first investigational treatment that combines GLP-1 and amylin receptor agonism biology in one molecule, working on distinct pathways and offering complementary effects on appetite control. The findings published and presented today are encouraging. We are excited to advance the clinical development of subcutaneous and oral amycretin into phase 3 to assess its potential as a therapeutic option for weight management.' The published once-daily oral amycretin phase 1 clinical trial data showed that participants receiving amycretin achieved greater weight loss compared to placebo.3 After 12 weeks of treatment with amycretin up to 50 mg and up to 2 times 50 mg, participants achieved a mean change in body weight of -10.4% and -13.1% respectively, compared to -1.2% with placebo.3 There were no apparent signs of weight loss plateauing within the 12 weeks of treatment in either of these amycretin-treated groups.3 Once-daily oral amycretin appeared to have an acceptable safety profile and was tolerable in all tested doses, with TEAEs in line with what was expected from targeting GLP-1 and amylin receptors.3 All reported TEAEs occurred in a dose-proportional manner, were mild to moderate in severity, and mostly gastrointestinal. No new safety signals appeared during the study.3 Based on the findings from the oral and subcutaneous amycretin trials, Novo Nordisk recently announced it will advance amycretin into phase 3 trials to further investigate the treatment as a potential new therapeutic option for weight management.4 About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and for adults with type 2 diabetes. Amycretin is developed for subcutaneous and oral administration. Oral amycretin Phase 1 trial – The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in 144 people with overweight or obesity, with a total treatment duration of up to 12 weeks. Subcutaneous amycretin Phase 1b/2a trial – The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in 125 people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information _______________________ References The Lancet: Dahl K, Toubro, S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: Results of a randomised, controlled, phase 1b/2a study. Dahl, K, et al. (2025). Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist: Results of a Phase 1b/2a Clinical Trial. Poster 2002-LB. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025. The Lancet: Gasiorek A, Heydorn A, Gabery S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, randomised, placebo-controlled study. Novo Nordisk Company Announcement. Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development. Available at: Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
13 hours ago
Diabetes drug may cut migraine days in half with little weight loss: Study
Drugs in the same family as Ozempic and Wegovy are known for treating diabetes and helping with weight loss, but a small, early-stage study suggested they might also ease migraines -- even when there's no weight loss. The benefit appears to come from lowering pressure in the brain, Dr. Simone Braca, a neurologist at the University of Naples Federico II and lead author of the study, explained to ABC News. 'This study is very interesting in that the GLP 1s are hypothesized to lower brain pressure, which can then lower your chance of getting a headache or a migraine,' Braca said. The small, 12-week study tracked 26 adults with obesity who had chronic or frequent migraines. Published in Headache -- the official journal of the American Headache Society -- and presented at this week's European Academy of Neurology meeting in Finland, it tested liraglutide, a type of GLP-1 drug commonly used for diabetes and weight loss. After taking a daily 1.8 mg dose of liraglutide for three months -- the amount typically used to treat diabetes -- their average number of headache days per month dropped from 20 to about nine. Participants also reported less disability from migraines, with scores on a standard headache impact scale cut by more than half. Although some participants lost a small amount of weight, Braca said the few lost pounds were not meaningful enough to explain the improvement in migraines. Instead, Braca pointed to pressure from cerebrospinal fluid -- the liquid that surrounds and cushions the brain and spine. He said he believes that even slight buildups of this fluid can press on nearby veins and nerves in the brain, potentially triggering migraines. 'An increased pressure of the spinal fluid in the brain may be one of the mechanisms underlying migraine,' Braca said. 'And if we target this mechanism, this preliminary evidence suggests that it may be helpful for migraine.' Nearly half of patients reported at least a 50% reduction in headache days, according to the Headache paper. About 40% experienced mild side effects like nausea or constipation. None stopped taking the medication. With such promising results, Braca and his research team, led by Dr. Roberto De Simone, are already planning larger trials. Future studies will measure brain pressure more directly and explore whether other GLP 1 drugs might also offer the same relief but with fewer side effects. 'There are still a substantial portion of migraine patients that face an unmet need and that live with its burden,' he said. 'New drugs that could target other pathways, I think that could be reassuring to those patients and give them hope.' The study adds to growing evidence that GLP-1 drugs may have benefits beyond diabetes and weight loss. Researchers are already studying these medications for a range of other conditions, including reducing the risk of heart disease and stroke, easing symptoms of addiction and treating Alzheimer's disease.
